Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glutamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.55 |
| ▸ | GRM6 | O15303 | 2/20 | 0.55 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.55 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.55 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.55 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL27218911 | 1.00 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL2201557 | 1.00 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL16290410 | 1.00 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL27572769 | 1.00 | GRM8 (0.55) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL194964 | 0.96 | GRM8 (0.50) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL27622200 | 0.96 | GRM8 (0.50) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL19856868 | 0.94 | GRM8 (0.49) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL29255769 | 0.94 | CYP1A2 (0.49) | GRM8GRM6GRM7GRM4GRIN2D | |
| D-Glutamate SCHEMBL19856866 | 0.94 | GRM8 (0.49) | GRM8GRM6GRM7GRM4GRIN2D | |
| Glutamic Acid SCHEMBL8852502 | 0.94 | CYP1A2 (0.49) | GRM8GRM6GRM7GRM4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | claimed |
| EP-0891771-A1 | Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases | Health Now, Inc. (US) | 1999-01-20 | — | — | EP | claimed |
| US-4761471-A | INDUCE BONE FORMATION IN ANIMALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1988-08-02 | — | — | US | claimed |
| EP-4709397-A1 | METHOD FOR PRODUCING THERAPEUTIC RNA PLATELET VEHICLES | HemostOD SA (CH) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024231345-A1 | METHOD FOR PRODUCING THERAPEUTIC RNA PLATELET VEHICLES | HEMOSTOD SA (CH) | 2024-11-14 | — | — | WO | disclosed |
| US-20240207376-A1 | Compositions and Methods for Treating Celiac Sprue Disease | UNIVERSITY OF WASHINGTON | 2024-06-27 | — | — | US | disclosed |
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| CN-115684456-A | Method for controlling ion exchange chromatography and ion exchange chromatography | 日本株式会社日立高新技术科学 | 2023-02-03 | — | — | CN | disclosed |
| CN-115612679-A | Acetyl coenzyme A acetyltransferase mutant and application thereof | 李岩 | 2023-01-17 | — | — | CN | disclosed |
| CN-109890367-B | Highly concentrated, low viscosity MASP-2 inhibitory antibody formulations, kits and methods | 奥默罗斯公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4023243-A2 | COMPOSITIONS AND METHODS FOR TREATING CELIAC SPRUE DISEASE | University of Washington through its Center for Commercialization (US) | 2022-07-06 | — | — | EP | disclosed |
| US-5891673-A | ISOLATED MURINE LYMPHOCYTE SPECIFIC TYROSINE KINASE BINDING PROTEIN; TREATMENT CANCER, HIV, AUTOIMMUNE DISORDERS, MULTIPLE SCLEROSIS, JUVENILE DIABETES AND RHEUMATOID ARTHRITIS | SYNTEX (U.S.A.) INC. (US) | 1999-04-06 | — | — | US | disclosed |
| EP-0891771-A1 | Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases | Health Now, Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5438120-A | Purified Bordetella pertussius antigen used in vaccine against whooping cough; side effect reduction | BURROUGHS WELLCOME CO. (US) | 1995-08-01 | — | — | US | disclosed |
| US-5210083-A | Aqueous solutions containing taurolidine or taurultam and polyol; bactericides | ED. GEISTLICH SOHNE A.G. FUR CHEMISCHE INDUSTRIE (CH) | 1993-05-11 | — | — | US | disclosed |
| US-5141870-A | Transforming plants with mutant fragment confers herbicide resistance | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-25 | — | — | US | disclosed |
| US-5013659-A | Hybrid to resist sulfonylureas | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-07 | — | — | US | disclosed |
| US-5000953-A | Biologically active substance | KAKEN CHEMICAL CO., LTD. (JP) | 1991-03-19 | — | — | US | disclosed |
| EP-0253662-B1 | PHARMACEUTICAL COMPOSITIONS | ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE (CH) | 1990-11-14 | — | — | EP | disclosed |
| EP-0253662-A1 | Pharmaceutical compositions | ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE (CH) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793855-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | GRM8 4711/4885GRM6 4731/4885GRM7 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.